OBJECTIVE: Vitamin D (D 3 ) status is reported to correlate negatively with insulin production and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). However, few placebo-controlled intervention data are available. We aimed to assess the effect of large doses of parenteral D 3 on glycosylated haemoglobin (HbA 1c ) and estimates of insulin action (homeostasis model assessment insulin resistance: HOMA-IR) in patients with stable T2DM. MATERIALS AND METHODS: We performed a prospective, randomised, double-blind, placebo-controlled pilot study at a single university care setting in Switzerland. Fifty-five patients of both genders with T2DM of more than 10 years were enrolled and randomised to either 300,000 IU D 3 or placebo, intramuscularly. The primary endpoint was the intergroup difference in HbA 1c levels. Secondary endpoints were: changes in insulin sensitivity, albuminuria, calcium/phosphate metabolism, activity of the renin-aldosterone axis and changes in 24-hour ambulatory blood pressure values. RESULTS: After 6 months of D 3 supply, there was a significant intergroup difference in the change in HbA 1c levels (relative change [mean ± standard deviation] +2.9% ± 1.5% in the D 3 group vs +6.9% ± 2.1% the in placebo group, p = 0.041) as HOMA-IR decreased by 12.8% ± 
Introduction
Epidemiological and observational evidence suggests that vitamin D (D 3 ) supply inversely correlates with the risk for T2DM and, once diabetic, serum 25(OH)-D 3 levels correlate inversely with impaired glucose tolerance [1, 2] . Since cardiovascular events are greatly increased in T2DM, it has been suggested that D 3 status measured as serum 25(OH)-D 3 levels might be a modifiable risk factor for cardiovascular events in T2DM patients, as well as in the general population [1, 2] . D 3 is required for and improves the production of insulin, and is also implicated in the mechanism of insulin action [3, 4] . However, in both nondiabetic and diabetic patients, the clinical associations of D 3 with insulin resistance and beta-cell function are inconsistent [2, 5, 6] , and reported intervention studies employing D 3 either as 25(OH)-D 3 (e.g., cholecalciferol) or as 1,25(OH) 2 -D 3 (e.g., calcitriol) have yielded conflicting results that are difficult to interpret owing to lack of placebo control [7, 8] . Supplementation of D 3 and calcium (400 IU D 3 and 1000 mg calcium daily) did not reduce the risk of developing diabetes in the Women' s Health Study over 7 years of follow-up [7] and supplementation of D 3 in normal subjects (20, 000 IU D 3 orally twice weekly for 6 months) did not affect insulin secretion nor sensitivity [8] , whereas supplementing 700 IU D 3 daily over 3 years was found to attenuate the increases in glycaemia and insulin resistance in elderly subjects with impaired fasting glucose at baseline [9] . In a short-term study (4 weeks) in nondiabetic subjects with D 3 deficiency (25(OH)-D 3 <25 nmol/l) two oral doses of D 3 (100,000 IU D 3 2 weeks apart) had no significant effect on serum glucose, insulin concentration and insulin sensitivity assessed with an oral glucose tolerance test [10] . However, in a study of subjects at risk for T2DM, oral supplementation of D 3 (2,000 IU D 3 daily for 4 months) was shown to improve beta-cell function, but not insulin sensitivity [11] . Results from randomised controlled trials that evaluated the specific effects of 25(OH)-D 3 or 1,25(OH) 2 -D 3 (without also adding calcium to D 3 ) on glucose and insulin homeostasis in T2DM patients have been conflicting [2, [12] [13] [14] [15] [16] [17] [18] [19] [20] . A recently published systematic review examining the effect of vitamin D supplementation in 15 newer published studies [21] again found discrepancies in outcomes, which may be due to heterogeneous study populations (number of patients included, stage of diabetes, gender, age, oral or insulin treatment) or to heterogeneous interventions (oral, parenteral, dose, duration). In view of the suggestive but inconclusive evidence for a clinically important effect of exogenous D 3 supplementation on glucose and insulin homeostasis in both normal and diabetic subjects and as few placebo-controlled intervention data are available, we wished to assess insulin sensitivity to large doses of D 3 in a double-blinded, randomised, placebo-controlled trial in stable T2DM patients. In addition, in view of the lack of information on responses of calcium/phosphate metabolism, calci-/phosphotropic hormones and 24-hour ambulatory blood pressures to large doses of D 3 in T2DM patients, this study also explored these data.
Methods

Study design and treatment protocol
This prospective, randomised, double-blind, placebo-controlled pilot study was performed at a single university care setting in Switzerland. The study was approved by the local internal review board (EKBB, University of Basel), the study subjects gave written, informed consent and were paid CHF 50.00 for each office visit. Patients were recruited from the ambulatory care facilities (diabetology and cardiology) of the hospital. Randomisation was performed by a pharmacist using a computer program. He provided the randomisation codes and vials containing D 3 or 0.9% NaCl. A nurse not involved in the study administered the injections, either D 3 (cholecalciferol, 300,000 IU, 1 ml intramuscularly, vitamin D3 Streuli Inc., Switzerland), or placebo (0.9% NaCl, 1 ml intramuscularly) in a blinded way. After 3 months, all patients received a blinded repeat injection which contained either 0.9% NaCl 0.5 ml (placebo arm or for D 3 replete patients in the D 3 arm) or D 3 150,000 IU, 0.5 ml (only patients in the D 3 arm when serum 25(OH)-D 3 levels were below 80 nmol/l in the D 3 arm and hypercalcaemia of any degree and hypercalciuria [≥8 mmol/24 hours] remained absent). An independent (nonstudy) physician evaluated the serum 25(OH)-D 3 and calcium results and allocated D 3 /NaCl administration via the hospital pharmacist who had provided the randomisation code.
Inclusion criteria
Men and nonpregnant women aged ≥18 years, with T2DM, living independently at home with stable blood glucose control for the past 2 months (less than 2 hypoglycaemic episodes in the past 2 months, unchanged doses of antihyperglycaemic agents in the last 3 months and stable glycosylated haemoglobin [HbA 1c ] levels for the past 6 months [variation by less than ±0.7%]). Blood pressure was to be stable below 145/85 mm Hg during the past 2 months under a fixed current regimen of blood pressure medications (if any) and/or potassium supplements (if any). Both diabetic and blood pressure therapies had to be judged as unlikely to require change in the subsequent 6 months by the referring diabetologist and cardiologist. It was prespecified that if changes in these medication regimens were needed during the study, these subjects would be regarded as dropouts and not included into the analysis. Biochemical assays and blood pressure measurements All biochemical analyses were performed in duplicate. All baseline measurements were done twice, 1 week apart and the baseline values reported are the means of these two measurements. Standard biochemical parameters in blood and 24-hour urine collections were determined by the hospital department of clinical chemistry using standard, stateof-the-art methodology as described in reference [22] . All subjects fasted overnight for 9 am blood draws. In insulin treated-patients, no insulin was administered after the final prescribed dose on the prior day. All oral medications were withheld until after the fasting blood draw. HbA 1c was determined by means of high performance liquid chromatography (HPLC). Homeostasis model assessment insulin resistance (HOMA-IR) was calculated using the published HOMA formula [23] . The following endocrine analyses were made with enzyme-linked immunosorbent assays: insulin, proinsulin, C-peptide, intact PTH, C-terminal FGF-23, plasma renin activity and plasma aldosterone. 25(OH)-D 3 , 1,25(OH) 2 -D 3 and tetrahydro-aldosterone (urine) were determined by means of HPLC. Twenty-fourhour blood pressure readings were recorded using Cardioline ® equipment. The equipment was used by an experienced study nurse.
Exclusion criteria
Statistical analysis
Randomisation was unstratified and unblocked. All analyses are based on the intention-to-treat population, comprising all randomised subjects. Intragroup comparisons (to own group baseline) and intergroup comparison (between the groups) were carried out using the paired t-test for biochemical data, and results are reported as arithmetic means and 95% confidence intervals. The Wilcoxon signed rank test was applied for the analysis of biochemical data that were not normally distributed (HbA 1c and HOMA-IR) and results are reported as geometric means. The effect of treatment was evaluated by calculating the percentage change from baseline for all variables studied for all analysis, a two-tailed p-value <0.05 was considered to indicate statistical significance. For analysis of the potential for differing treatment effects in patients with and without insulin treatment, two-way analysis of variance was used. Statistical analysis was performed using SSPS for Windows NT, version 20.0 (SSPS Inc., Chicago, IL).
Primary endpoint
Change in HbA 1c levels at 6 months.
Secondary, exploratory and safety endpoints
Changes in HOMA-IR (calculated as described in reference [23] ) at 3 and 6 months. Changes in calcium/phosphate metabolism, calci-/phosphotropic hormones. Changes in proinsulin levels, renin/aldosterone activity/concentration, 24-hour aldosterone excretion rate, 24-hour urinary albumin excretion, mean systolic and diastolic 24-hour blood pressure values, all at 3 and 6 months.
Results
A total of 142 patients with T2DM were recruited between October and December 2009, 77 were screened and 55 fulfilled the entry criteria, consented and were enrolled into the study (n = 29 to D 3 , n = 26 to the placebo group, ( fig. 1 ). Baseline characteristics of the study subjects are summarised in table 1. There were no significant differences between the two treatment groups at baseline (table 1, p-values). All of the 55 study participants completed the study ( fig. 1 ) and there was no change in either antihyperglycaemic drugs (insulin requirements) nor in the number and dose of antihypertensive drugs. fig. 2 ). There was also a significant treatment effect on HOMA-IR (table 2 and fig. 2 ): whereas HOMA-IR decreased by -12.8% ± 5.6% in the D 3 group, it increased by +10% ± 5.4% in the placebo group (p = 0.032). There was no significant difference in the serum levels of high-sensitivity C-reactive protein (hsCRP) as a marker of systemic in- 
Effects of D 3 on 24-hour ambulatory blood pressure
Twenty-four-hour ambulatory systolic and diastolic blood pressures decreased significantly within both groups with no significant intergroup difference (table 7) .
Adverse effects
One patient in the placebo group developed a small abscess at the injection site (after the 3-month injection), which healed without antibiotics or surgical intervention. No other side effects were reported.
Discussion
This study examined a population of slightly D 3 deficient (defined as <50 nmol/l [24] ), metabolically stable, longstanding (>10 years) T2DM patients with adequate baseline blood pressure and acceptable glycaemic control (HbA 1c 7.1% ± 1.0%, [26] , but this thesis was not supported by changes in hsCRP levels. However, both groups exhibited normal baseline hsCRP values, suggesting that systemic inflammatory activity was low and rendering demonstration of a putative inhibitory effect more difficult. Other studies examining the effects of D 3 in patients at risk for diabetes or normal subjects have failed to demonstrate a significant effect of the intervention on insulin sensitivity [9] [10] [11] . Thus, the effect of D 3 may be limited to establish T2DM and may depend on the degree of insulin resistance. 1.08 ± 0.12 (1.03 to 1.13)
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1.14 ± 0.12 (1.09 to 1.19) Urea (mmol/l) 6.8 ± 2.5 (5.9 to 7.8) 6 .9 ± 2.1 (6.1 to 7.7) 7.5 ± 2.6 (6.5 to 8.5) 6.8 ± 2.8 (5.7 to 7.9) 7.0 ± 2. 3 (the recruited subjects all live~47 o N latitude). However, as a result of patient factors (holidays, professional engagements, etc.) enrolment could be completed only at the end of December. The last subjects completed the protocol in July 2010, thereby natural sun exposure increased D 3 in both groups. The effect of D 3 administration may have been mitigated by the fact that the placebo group exhibited a "spontaneous" increase in 25(OH)-D 3 levels most probably owing to increased sun exposure in the spring and early summer. A small but significant reduction of C-peptide levels was noted in the D 3 arm relative to placebo. This finding is consistent with the observed tendency to a relative reduction of fasting glucose levels in the D 3 arm and may thus reflect a secondary consequence of improved insulin sensitivity. Previously, 1,25(OH) 2-D 3 has been shown to inhibit renin gene transcription and vitamin D receptor knockout mice demonstrate hypertension [27, 28] . However, this study in T2DM with well-controlled blood pressure did not show evidence for a detectable inhibitory effect of D 3 on the activity of the renin/aldosterone system on the basis of the analysis of plasma renin, plasma aldosterone and 24-hour urinary excretion rates of tetrahydro-aldosterone. Also, there was no intergroup treatment difference in the 24-hour ambulatory systolic and diastolic blood pressure measurements. The observation of a significant decrease in urinary albumin excretion in the D 3 group is of interest in view of the association of low D 3 status with albuminuria [29] and is confirmatory evidence for the possible retarding effect of D 3 agonists on progression of glomerular injury [30] . Our study cannot conclusively answer the question as to whether the observed effects of D 3 [32] , and elevated FGF-23 levels have been reported to be independently associated with total mortality in a prospective patient cohort with in- cident end-stage renal disease [33, 34] . The role of FGF-23 in the incidence of coronary heart disease (CHD) in the general population is unclear. However, there is substantial reason to consider that incident CHD is not dependent on FGF-23 levels in the general population. In a prospective, nested, case-control cohort study, from the 51,529-subject Health Professionals Follow-up Study, within the subset with no history of CHD (mean serum creatinine 1.0 mg/ dl) no association was found between baseline FGF-23 levels and subsequent nonfatal myocardial infarction and fatal CHD events [35] . Nevertheless, other epidemiological data have shown that FGF-23 concentration is a risk factor for increased all-cause and cardiovascular mortality in Swedish community dwelling adults [36] . Interestingly, it has been demonstrated that insulin-resistant T2DM patients exhibit an impaired FGF-23 and PTH response to an acute phosphate load, sufficient to result in a supernormal hyperphosphataemic response [37] . Higher postprandial serum phosphate in T2DM might account, at least in part, for the systemic vascular calcification observed in this disorder and its status as a cardiovascular risk factor, as a function of duration of diabetes [38] , and thus it is possible that higher FGF-23 levels might mitigate diabetic vascular disease, at least in subjects without chronic kidney disease. Since FGF-23 is produced in osteoblasts and osteocytes, and osteocyte density is reduced in experimental diabetes [39] , it has been suggested that T2DM may be a state of relative FGF-23 hyporesponsiveness [37] . In fact, osteoblast-specific deletion of the insulin receptor in mice results in a phenotype of systemic insulin resistance and obesity that is mediated in part by osteoblastic endocrine dysfunction characterised by diminished secretion of under-carboxylated osteocalcin [40] . The findings that D 3 induced increases in FGF-23 levels in T2DM, as previously reported in non-diabetics [41] , and that D 3 can improve the course of HBA 1c and insulin sensitivity of peripheral tissues (HOMA-IR), raises the possibility that D 3 therapy in T2DM, in addition to improving insulin sensitivity for glucose homeostasis in muscle cells and hepatocytes, might also result in increased FGF-23 levels via a similar insulinsensitising action in osteocytes/osteoblasts. The strengths of the present study are the placebo-controlled, prospective study design and the fact that no potentially confounding concomitant medication changes were made during the observation period. The chief limitation of this study is the relatively small number of participants and single centre location. In addition, the "spontaneous" rise in 25(OH)-D 3 levels in the control population may have narrowed the differences and we cannot assume that the effects are dependent on different D 3 doses. Also, we cannot exclude an additional effect of clandestine use of D 3 in the placebo group as a result of the subjects' interest in the study hypothesis. Our results encourage the design and conduct of studies that further explore the roles of D 3 and D 3 analogues on glycaemic control in T2DM patients. Future studies should -among many other points -establish the dose-response characteristics, examine the best analogue of D 3 with regard to the benefit/harm ratio and evaluate the effects in larger study populations and over longer time periods. In view of our study results, the effects of D 3 on beta-cell function and insulin secretion merit special attention. In addition, the relevance of increased FGF-23 on cardiovascular morbidity should be evaluated in diabetes. In summary and conclusion, D 3 improved insulin sensitivity (based on HOMA-IR) and affected the course of HbA 1c positively compared to placebo in patients with T2DM, but did not weaken, and was well tolerated. 
Original article
Swiss Med Wkly. 2014;144:w13942 It had been planned to enrol all patients between October and November to limit the contribution of skin synthesis of D
Figures (large format)
